Member Info for D0berman

Uncle Alastair running 3pm Carlisle 4-1 - got to be worth a fiver!!

SIGNIFICANCE STATEMENT
Study of the in vivo biotransformation of Trastuzumab and Pertuzumab in patients undergoing therapy for Her-2-positive breast cancer. Methodology based on enrichment from plasma using AFFIMERS followed by separation of charge variants by pH-gradient, cation-exchange chromatography. Comparative analysis of the chromatographic traces showed that in vitro stress testing mimicks in vivo biotransformation to a large extend as far charge variants are concerned. This paves the way to studies on other therapeutic antibodies.

WTF!! hahahah

FFS - what's the most relevant?

Just did dummy sell for 5000 shares - okay here.

HL updated - all ready to go.

Dear Mr Jones

Thank you for contacting us, I hope you are well.

I have referred your query to the Corporate Action Team who have informed me they are looking to send the communications regarding Avacta shortly. The Open Offer entitlements are due to be issued on Friday and our clients will be able to submit an instruction once the accounts have been credited with the entitlements and we've added the voting facility.

I hope this has been of assistance. If you have any other questions, please get back to me.

https://www.trinitydelta.org/research-notes/diagnostics-ma-led-growth-strategy-is-ready-to-launch/

25 minutes agoI
nvestment Perspective
Avacta employs its two proprietary platforms, Affimer and pre|CISION, to create novel diagnostic and therapeutic products. The COVID-19 pandemic thrust its ability to develop an Affimer-based LFT (lateral flow test) diagnostic into the spotlight, even though we believe greater long-term value lies within Therapeutics applications. While the COVID-19 opportunity didn’t pan out as many investors expected, it did showcase Avacta’s diagnostics capabilities and Affimers’ potential. Lead therapeutic asset AVA6000 is progressing through Phase I and should confirm the clinical utility of pre|CISION. A wider portfolio of products is being readied to exploit the platform’s tumour specific activation, which should result in greater potency and less toxicity. News flow over the next 18-24 months provides multiple value-inflection points. Our valuation is £557m, equivalent to 219p/share, from £710m, 280p/share previously.

From WalesOnline just now.

Children could be sent home from school to work remotely again this winter with further waves of Covid expected this winter, headteachers are warning. Health bosses have forecast a Covid and flu "twindemic" and one of Wales' top doctors said "one of more waves" of Covid are expected in coming months.

Me too - on my 3rd strong black already - but wahoo!! SYME have secured a £1mil loan, come on SupplyMe!!!!!!!

10/3 gotta be done!!

Haha - had to look that up!!

Eleftheria Ledaki, cRTTP
Eleftheria Ledaki, cRTTP
• Following
Director, Business Development and Alliance Management at Avacta
3d • 3 days ago

Such a pleasure to interview Marina Hatsopoulos. Take a look at our podcast as part of the ARISTEiA in 30minutes podcast series!

#interview #startups #innovation #careerdevelopment #podcast #success #mentoring
ARISTEiA
ARISTEiA
4d • 4 days ago

Follow
The new podcast of the ARISTEiA – Institute for the Advancement of Research and Education in Arts, Sciences and Technology, is now on air. Marina Hatsopoulos, Chair of the Board of Levitronix Technologies & President of Hellenic Innovation Network, USA, discuses with Eleftheria Ledaki, Director, Business Development and Alliance Management at Avacta, UK, about "Starting business up and getting them on success track" .
Listen on Spotify here --> https://lnkd.in/dsNV5Pfi
#success #education #business

Back on

yep

cannot even 1000 shares with HL!

Naughty, naughty, naughty Tommy!!

vrmnnd - Exactly!

He's joking butties!!!!!!